Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05% (NCT03212963) | Clinical Trial Compass
TerminatedPhase 4
Evaluation of Adrenal Suppression Potential and Pharmacokinetics of Halobetasol Lotion 0.05%
Stopped: Sponsor's Decision
United States16 participantsStarted 2017-03-21
Plain-language summary
The objective of this open-label multicentric study is to determine the adrenal suppression potential and the pharmacokinetic (PK) properties of halobetasol lotion (HBP) applied twice daily for up to two weeks in subjects aged 12 to 16 years 11 months with stable plaque psoriasis. Subject enrollment will continue until at least 20 subjects with both screening and end of study (EOS) serum cortisol data (pre- and pos-tcosyntropin stimulation) have completed the study without any significant protocol violations (evaluable subjects). This may require the enrollment of approximately 25 subjects.
Who can participate
Age range12 Years – 16 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Subject is male or non-pregnant female and is 12 to 16 years 11 months of age.
✓. Subject has provided written informed assent and was accompanied by the parent or legal guardian at the time of assent/consent signing. The parent or legal guardian has provided informed consent for the subject. 3. Subject has a clinical diagnosis of stable plaque psoriasis involving a minimum of 10% body surface area (BSA) within the Treatment Area. The "Treatment Area" is defined as the entire body exclusive of the face, scalp, groin, axillae, and other intertriginous areas.
Exclusion criteria
✕. Subject has spontaneously improving or rapidly deteriorating plaque psoriasis.
✕. Subject has guttate, pustular, erythrodermic or other non-plaque forms of psoriasis.
✕. Subject has a physical condition which, in the investigator's opinion, might impair evaluation of plaque psoriasis, adrenal axis function (e.g., Addison's Disease, Cushing's Syndrome) or which exposes the subject to an unacceptable risk by study participation.
✕. Subject has used any phototherapy (including laser), photochemotherapy or systemic psoriasis therapy including methotrexate, retinoids, cyclosporine or biologics within 30 days prior to the initiation of treatment with the test article.
What they're measuring
1
Investigator's Global Assessment
Timeframe: Day 15
2
Percent BSA Affected With Disease
Timeframe: Day 15
3
Percent Body Surface Area Treated With Test Article
Timeframe: Day 8
4
Number of Subjects With Abnormal Hypothalamus-Pituitary-Adrenal Axis Response
✕. Subject has used systemic corticosteroids (including oral or intramuscular) or topical, inhaled or intranasal corticosteroids within 30 or 14 days, respectively, prior to Part B of the Screening Visit and/or the subject has used systemic or topical corticosteroids between Part B of the Screening Visit and the initiation of treatment.
✕. Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to the initiation of treatment or is intending to have such exposure during the study that is thought by the investigator to likely modify the subject's disease.
✕. Subject has used topical psoriatic therapy including tar, anthralin, retinoids, vitamin D analogs (e.g., Dovonex®) within 14 days prior to the initiation of treatment with the test article.
✕. Subject has used emollients/moisturizers on areas to be treated within one day prior to the initiation of treatment with the test article.